Cargando…

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring

Asparaginase is widely used in chemotherapeutic regimens for the treatment of acute lymphoblastic leukemia (ALL) and has led to a substantial improvement in cure rates, especially in children. Optimal therapeutic effects depend on a complete and sustained depletion of serum asparagine. However, pron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asselin, Barbara, Rizzari, Carmelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732456/ https://www.ncbi.nlm.nih.gov/pubmed/25586605 http://dx.doi.org/10.3109/10428194.2014.1003056

Ejemplares similares

Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi
por: Tong, Wing H., et al.
Publicado: (2023)

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
por: Siebel, Christian, et al.
Publicado: (2021)

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
por: Baruchel, André, et al.
Publicado: (2020)

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data
por: Würthwein, Gudrun, et al.
Publicado: (2021)

Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
por: Rizzari, Carmelo, et al.
Publicado: (2014)

Asparaginase: an old drug with new questions
por: Cecconello, Daiane Keller, et al.
Publicado: (2020)

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia
por: Khalil, Alaeddin, et al.
Publicado: (2020)

Development of a UPLC-MS/MS method for the therapeutic monitoring of L-asparaginase
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2018)

New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs)
por: Sommerfeld-Klatta, Karina, et al.
Publicado: (2020)

ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment
por: Chiu, Martina, et al.
Publicado: (2021)

Chronopharmacology in Therapeutic Drug Monitoring—Dependencies between the Rhythmics of Pharmacokinetic Processes and Drug Concentration in Blood
por: Dobrek, Lukasz
Publicado: (2021)

Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring
por: Brocks, Dion R., et al.
Publicado: (2020)

Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
por: Villanueva-Flores, Francisca, et al.
Publicado: (2021)

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017)

Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics
por: Moschny, Nicole, et al.
Publicado: (2021)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy
por: Ding, Ye, et al.
Publicado: (2019)

Recent Strategies and Applications for l-Asparaginase Confinement
por: Nunes, João C. F., et al.
Publicado: (2020)

Pharmacokinetic drug-drug interaction and their implication in clinical management
por: Palleria, Caterina, et al.
Publicado: (2013)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP‐458)
por: Lin, Tong, et al.
Publicado: (2021)

Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
por: Lin, Tong, et al.
Publicado: (2023)

A Review of L-Asparaginase Hypersensitivity in Paediatric Acute Lymphoblastic Leukaemia Patients with Regard to the Measurement of Anti-Asparaginase Antibodies and Their Genetic Predisposition
por: Tan, Yan Qi, et al.
Publicado: (2023)

Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations
por: Monteiro, Joaquim F., et al.
Publicado: (2018)

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
por: Sabo, Amelia-Naomi, et al.
Publicado: (2021)

Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics
por: He, Shiyu, et al.
Publicado: (2021)

Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy
por: Van Trimpont, Maaike, et al.
Publicado: (2022)

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
por: Sime, Fekade Bruck, et al.
Publicado: (2012)

Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
por: Bellmann, Romuald, et al.
Publicado: (2017)

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
por: Egler, Rachel A., et al.
Publicado: (2016)

l-asparaginase: Need for an Expedition from an Enzymatic Molecule to Antimicrobial Drug
por: Vimal, Archana, et al.
Publicado: (2021)

Overview of Therapeutic Drug Monitoring
por: Kang, Ju-Seop, et al.
Publicado: (2009)

Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age
por: De Rose, Domenico Umberto, et al.
Publicado: (2020)

Current applications and different approaches for microbial l-asparaginase production
por: Cachumba, Jorge Javier Muso, et al.
Publicado: (2016)

Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production
por: Shishparenok, Anastasiya N., et al.
Publicado: (2023)

A Pharmacokinetic Study of Native E.coli Asparaginase for Acute Lymphoblastic Leukemia Treated with ThaiPOG Protocol
por: Chaweephisal, Phumin, et al.
Publicado: (2021)

Allergic Reactions to E. coli Asparaginase are Associated with Decreased Asparaginase Activity in an Indonesian Pediatric Population with ALL
por: Sari, Nur Melani, et al.
Publicado: (2023)

Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data
por: Umpiérrez, Martín, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ups28gktbgaaffupm434thgqus